Celtaxsys spins 'clin­i­cal­ly mean­ing­ful' da­ta on an­oth­er failed PhII cys­tic fi­bro­sis study

At first glance, you would think At­lanta-based Celtaxsys had plen­ty to be hap­py about in its re­lease about their Phase II study of an ex­per­i­men­tal drug for cys­tic fi­bro­sis called ace­bilu­s­tat. The an­ti-in­flam­ma­to­ry drug had pro­duced the first “clin­i­cal­ly mean­ing­ful” ev­i­dence of its po­ten­tial to re­duce pul­monary ex­ac­er­ba­tions in pa­tients.

That must be worth a cel­e­bra­tion, right?

But if you look at it close­ly, the da­ta — such as they are — leave a lot to be de­sired.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER